Skip to main content
SpringerLink
Log in

Schwerwiegende Komplikationen vermeiden

Antimykotische Prophylaxe bei hämatologischen Patienten

  • Supportivtherapie
  • Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Nach wie vor sind Patienten, die sich einer Stammzelltransplantation unterziehen, dem Risiko einer Pilzinfektion ausgesetzt, beispielsweise mit Candida albicans. Eine entsprechende Prophylaxe sollte daher Standard sein. Immer häufiger spielen auch Infektionen mit Aspergillus- und Mucorales-Spezies eine Rolle.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Vehreschild JJ et al. Clinical effectiveness of Posaconazole prophylaxis in patients with acute myelogenous leukemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65(7):1466–71.

    Article  CAS  Google Scholar 

  2. Slavin MA et al. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern Med J. 2008;38(6b):468–76.

    Article  CAS  Google Scholar 

  3. Goodman JL et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–51.

    Article  CAS  Google Scholar 

  4. Rotstein C et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis. 1999;28(2):331–40.

    Article  CAS  Google Scholar 

  5. Cornely OA et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2009;94(1):113–22.

    Article  Google Scholar 

  6. Maertens J et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 update. Bone Marrow Transplant. 2011;46(5):709–18.

    Article  CAS  Google Scholar 

  7. Slavin MA et al. Efficacy and safety of fluconazole prophylaxis for gunal infections after marrow transplantation — a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.

    Article  CAS  Google Scholar 

  8. Glasmacher A et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother. 2006;57(2):317–25.

    Article  CAS  Google Scholar 

  9. Cornely OA et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4):348–59.

    Article  CAS  Google Scholar 

  10. Ullman AJ et al. Posaconazole or Fluconazole for Prophylaxis in severe graft-versus-hostdisease. N Engl J Med. 2007;356(4):335–47.

    Article  Google Scholar 

  11. Wingard JR et al. Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010; 116(24):5111–8.

    Article  CAS  Google Scholar 

  12. Van Burik JA et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–16.

    Article  Google Scholar 

  13. Hashino S et al. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol. 2008;87(1):91–7.

    Article  Google Scholar 

  14. Nihtinen A et al. Low incindence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis. Transpl Infect Dis. 2012;14(1):24–32.

    Article  CAS  Google Scholar 

  15. El-Cheikh J et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39(5):301–6.

    Article  CAS  Google Scholar 

  16. Peterson L et al. Posaconazole prophylaxis—impact on incidence of invasive fungal disease and antifungal treatment in haematological patients. Mycoses. 2013;56(6):651–8.

    Article  CAS  Google Scholar 

  17. Kraft WK et al. Posaconazole tablet pharmacokinetics: Lack of effect on concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrobial Agents Chemother. 2014;58(7):4020–5.

    Article  Google Scholar 

  18. Pham AN et al. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections. Mycoses. 2016;59(4):226–33.

    Article  CAS  Google Scholar 

  19. Maertens JA et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus or other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9.

    Article  CAS  Google Scholar 

  20. Gebremariam T et al. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. Antimicrob Agents Chemother. 2017;61(5):e02589–16.

    Article  CAS  Google Scholar 

  21. Cornely OA et al. Safety and pharmacokinetics of Isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrobial Agents Chemother. 2015;59(4):2078–85.

    Article  CAS  Google Scholar 

  22. Cornely OA et al. AmBiGuard Study Group. Randomized comparison of liposomales Amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblasic leukemia. J Antimicrobial Chemother. 2017;72(8):2359–67.

    Article  Google Scholar 

  23. Mattiuzzi GN et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50(1):143–7.

    Article  CAS  Google Scholar 

  24. Cordonnier C et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762–8.

    Article  CAS  Google Scholar 

  25. Cornet M et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol. 1999;20(7): 508–13.

    Article  CAS  Google Scholar 

  26. Moriyama B et al. Adverse Interactions between antifungal Azolen and vincristine: Review and analysis of cases. Mycoses. 2012;55(4):290–7.

    Article  CAS  Google Scholar 

  27. Trifilio S et al. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant. 2004;33(7):735–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik V — Hämatologie, Onkologie u. Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland

    Gerlinde Egerer

Authors
  1. Gerlinde Egerer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerlinde Egerer.

Additional information

Für die Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie (AGSMO) AGSMO im Internet: www.agsmo.de

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Egerer, G. Antimykotische Prophylaxe bei hämatologischen Patienten. Im Focus Onkologie 21, 34–37 (2018). https://doi.org/10.1007/s15015-018-3890-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-3890-5

Search

Navigation